CINV Guideline — Part 1: Emetogenic Classification and Risk Factors

Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.

guidelines•Mar 2026•guidelines

Pathophysiology of Chemotherapy-Induced Emesis

Chemotherapy-induced nausea and vomiting results from activation of multiple neural pathways. Understanding these pathways is essential for rational antiemetic selection.

Emetic Reflex Arc

The vomiting center — a functional region in the lateral medullary reticular formation — coordinates the emetic reflex. It receives afferent input from four principal sources:1

  1. Chemoreceptor trigger zone (CTZ): Located in the area postrema on the floor of the fourth ventricle, outside the blood-brain barrier. The CTZ detects emetogenic substances in the blood and cerebrospinal fluid. Key receptors include dopamine D2, serotonin 5-HT3, and neurokinin-1 (NK1) receptors.

  2. Vagal afferents from the gastrointestinal tract: Chemotherapy agents cause enterochromaffin cells in the GI mucosa to release serotonin (5-HT), which stimulates vagal 5-HT3 receptors. This is the primary mechanism for acute emesis (within the first 24 hours).

  3. Vestibular system: Contributes to motion-related and positional nausea; histamine H1 and muscarinic M1 receptors are involved.

  4. Higher cortical centers: Mediate anticipatory nausea and vomiting through conditioned responses involving limbic pathways.

Neurotransmitter Pathways

NeurotransmitterReceptorPrimary Role in CINVTargeted By
Serotonin (5-HT)5-HT3Acute phase (0–24 h); vagal afferent stimulationOndansetron, granisetron, palonosetron
Substance PNK1Delayed phase (24–120 h); central and peripheral pathwaysAprepitant, fosaprepitant, netupitant, rolapitant
DopamineD2CTZ activation; gastric stasisMetoclopramide, prochlorperazine, haloperidol
HistamineH1Vestibular input; cortical pathwaysDiphenhydramine, promethazine
AcetylcholineM1Vestibular and central pathwaysScopolamine
GABAGABA-ACortical/anticipatory pathwaysLorazepam, alprazolam
EndocannabinoidsCB1/CB2Central antiemetic modulationDronabinol, nabilone

Types of Chemotherapy-Induced Nausea and Vomiting

Acute CINV

  • Onset: Within the first 24 hours of chemotherapy administration
  • Peak: Typically 5 to 6 hours after treatment
  • Mechanism: Primarily serotonin-mediated via vagal afferents from the GI tract
  • Prevention: 5-HT3 receptor antagonists are the cornerstone of acute prophylaxis

Delayed CINV

  • Onset: More than 24 hours after chemotherapy, typically peaking at 48 to 72 hours
  • Duration: May persist for up to 5 to 7 days
  • Mechanism: Primarily substance P/NK1 receptor-mediated; additional mechanisms include disruption of GI motility and blood-brain barrier permeability changes
  • Key agents associated with delayed CINV: Cisplatin, carboplatin, cyclophosphamide, doxorubicin, oxaliplatin
  • Prevention: NK1 receptor antagonists, dexamethasone, and olanzapine are the primary agents for delayed-phase prophylaxis

Anticipatory CINV

  • Definition: Nausea and/or vomiting occurring before chemotherapy administration, triggered by conditioned responses (sights, smells, or thoughts associated with prior treatment)
  • Incidence: Occurs in approximately 18% to 57% of patients by the fourth chemotherapy cycle2
  • Risk factors: Prior poorly controlled acute or delayed CINV is the strongest predictor
  • Management: Prevention of acute and delayed CINV is the most effective strategy; benzodiazepines (lorazepam) and behavioral interventions may be helpful once established

Breakthrough CINV

  • Definition: Nausea and/or vomiting that occurs despite receipt of optimal prophylactic antiemetic therapy
  • Management: Requires addition of an agent from a different pharmacological class than those used for prophylaxis (see Part 3)

Refractory CINV

  • Definition: Nausea and/or vomiting that occurs in subsequent chemotherapy cycles despite optimal prophylaxis and adequate rescue therapy in prior cycles
  • Management: Requires reassessment of the antiemetic regimen and consideration of adding or substituting agents

Emetogenic Classification of Intravenous Chemotherapy Agents

Emetogenic risk classification is the foundation of rational antiemetic prescribing. Agents are classified into four categories based on the expected frequency of emesis in the absence of antiemetic prophylaxis.3

CategoryEmesis Frequency Without Prophylaxis
High (HEC)>90% of patients
Moderate (MEC)30–90% of patients
Low (LEC)10–30% of patients
Minimal<10% of patients

High Emetogenic Potential (HEC) — Intravenous Agents

The following agents or regimens are classified as high emetogenic risk (>90% emesis frequency without prophylaxis):345

AgentTypical Emetogenic Dose ThresholdNotes
CisplatinAny dose (all doses ≥50 mg/m² are universally HEC; doses <50 mg/m² are often classified as MEC by some sources but treated as HEC by most guidelines)Most emetogenic single agent; strong delayed component
Cyclophosphamide≥1,500 mg/m²Lower doses classified as MEC
Carmustine (BCNU)>250 mg/m²Lower doses classified as MEC
Dacarbazine (DTIC)Any dose
Doxorubicin≥60 mg/m²Lower doses classified as MEC
Epirubicin≥90 mg/m²Lower doses classified as MEC
Ifosfamide≥2 g/m² per doseLower doses classified as MEC
Mechlorethamine (nitrogen mustard)Any dose
StreptozocinAny dose
AC combination (doxorubicin + cyclophosphamide)Any doseClassified as HEC regardless of individual agent doses
EC combination (epirubicin + cyclophosphamide)Any doseClassified as HEC regardless of individual agent doses
CarboplatinAUC ≥4Reclassified from MEC to HEC by updated guidelines

Note on combination regimens: The AC (doxorubicin/cyclophosphamide) and EC (epirubicin/cyclophosphamide) regimens are classified as HEC even though the individual agents at the doses used may individually be classified as MEC. Carboplatin-based regimens at AUC ≥4 have been reclassified as HEC by major guideline bodies based on studies showing high rates of delayed emesis and improved outcomes with HEC-level prophylaxis.5

Moderate Emetogenic Potential (MEC) — Intravenous Agents

The following agents are classified as moderate emetogenic risk (30–90% emesis frequency without prophylaxis):345

AgentNotes
Aldesleukin (IL-2)>12–15 million units/m²
Azacitidine
Bendamustine
CarboplatinAUC <4 (AUC ≥4 reclassified as HEC)
Carmustine≤250 mg/m²
Clofarabine
Cyclophosphamide<1,500 mg/m²
Cytarabine>200 mg/m² to 3 g/m²
Daunorubicin
Doxorubicin<60 mg/m²
Epirubicin<90 mg/m²
Etoposide (IV)
Idarubicin
Ifosfamide<2 g/m² per dose
Irinotecan
Melphalan (IV)>50 mg/m²
Methotrexate≥250 mg/m²
Oxaliplatin
Temozolomide (IV)
Thiotepa
Trabectedin
Trifluridine/tipiracil (IV formulation)

Low Emetogenic Potential (LEC) — Intravenous Agents

The following agents are classified as low emetogenic risk (10–30% emesis frequency without prophylaxis):345

AgentNotes
AtezolizumabImmune checkpoint inhibitor
Belinostat
Blinatumomab
Bortezomib
Brentuximab vedotin
Cabazitaxel
Carfilzomib
Cetuximab
Cytarabine100–200 mg/m²
Docetaxel
Doxorubicin (liposomal)
Durvalumab
Eribulin
Etoposide (IV, low dose)
Floxuridine
5-Fluorouracil
Gemcitabine
Ipilimumab
Ixabepilone
Melphalan (IV, low dose)≤50 mg/m²
Methotrexate50 to <250 mg/m²
Mitomycin
Mitoxantrone
Nab-paclitaxel
Nivolumab
Paclitaxel
Panitumumab
Pemetrexed
Pembrolizumab
Pertuzumab
Romidepsin
Temsirolimus
Topotecan
Trastuzumab
Trastuzumab emtansine (T-DM1)
Trastuzumab deruxtecan (T-DXd)Some sources classify as MEC
Vinflunine

Minimal Emetogenic Potential — Intravenous Agents

The following agents are classified as minimal emetogenic risk (<10% emesis frequency without prophylaxis):345

AgentNotes
Alemtuzumab
Asparaginase
Bevacizumab
Bleomycin
Busulfan
Cladribine (2-CdA)
Cytarabine<100 mg/m²
Daratumumab
Dexrazoxane
Fludarabine
Methotrexate<50 mg/m²
Nelarabine
Obinutuzumab
Ofatumumab
Pegaspargase
Pentostatin
Pixantrone
Pralatrexate
Ramucirumab
Rituximab
Vinblastine
Vincristine
Vinorelbine

Emetogenic Classification of Oral Chemotherapy Agents

Oral antineoplastic agents are increasingly used in oncology, and many carry significant emetogenic risk. Classification follows the same four-tier system.36

High/Moderate Emetogenic Potential — Oral Agents

AgentClassificationNotes
ProcarbazineHigh
Hexamethylmelamine (altretamine)Moderate–High
TemozolomideModerateCommonly used in CNS malignancies with concurrent radiation
Cyclophosphamide (oral)Moderate
Vinorelbine (oral)Moderate
CrizotinibModerate
ImatinibModerate
CeritinibModerate
BosutinibModerate
Trifluridine/tipiracil (Lonsurf)Moderate

Low Emetogenic Potential — Oral Agents

AgentNotes
Capecitabine
Etoposide
Fludarabine
Tegafur-uracil
Sunitinib
Everolimus
Lapatinib
Lenalidomide
Thalidomide
Ibrutinib
Idelalisib
Palbociclib
Ribociclib
Abemaciclib
Olaparib
Rucaparib
Niraparib
Dabrafenib
Trametinib
Vemurafenib
Cobimetinib
Encorafenib/binimetinib
Osimertinib
Afatinib
Sorafenib
Pazopanib
Axitinib
Cabozantinib
Lenvatinib
Regorafenib
Ponatinib
Venetoclax

Minimal Emetogenic Potential — Oral Agents

AgentNotes
Chlorambucil
Hydroxyurea
Melphalan (oral, low dose)
Methotrexate (oral)
6-Mercaptopurine
6-Thioguanine
Erlotinib
Gefitinib
Pomalidomide
Vismodegib
Sonidegib

Risk Factors for CINV

The likelihood and severity of CINV are determined by a combination of treatment-related and patient-related factors. Accurate risk assessment must incorporate both categories to guide antiemetic selection.7

FactorImpact
Emetogenic potential of the chemotherapy agent(s)Single strongest predictor of CINV risk
Chemotherapy doseHigher doses increase emetogenic risk (dose-dependent classification for many agents)
Combination chemotherapyEmetogenic risk is additive; combination regimens may exceed the classification of any individual agent
Route of administrationIV bolus generally more emetogenic than prolonged infusions
Rate of infusionRapid infusions may increase emetic risk
Multi-day regimensCumulative emetogenic effect; more complex antiemetic scheduling required
Concurrent radiation therapyCombined chemoradiation has increased emetogenic risk beyond either modality alone
FactorImpact on CINV Risk
Female sexIncreased risk (approximately 1.5- to 2-fold)
Younger age (<50 years)Increased risk; older patients generally have lower risk
History of low alcohol intakePatients with lower chronic alcohol consumption have higher CINV risk; chronic heavy alcohol use is protective
History of motion sicknessIncreased risk
History of morning sickness (hyperemesis gravidarum)Increased risk
History of prior CINVStrongest patient-related predictor; prior poorly controlled CINV significantly increases risk in subsequent cycles
Anxiety and expectationsHigher baseline anxiety and expectation of nausea increase risk of both acute and anticipatory CINV
Genetic polymorphismsVariations in hepatic enzyme (CYP2D6) and 5-HT3 receptor genes can affect antiemetic drug metabolism and receptor sensitivity
Performance statusDebilitated patients may have increased susceptibility

Determination of Emetogenic Risk for Combination Regimens

When patients receive combination chemotherapy, the emetogenic risk of the regimen should be determined as follows:3

  1. Identify the most emetogenic agent in the regimen
  2. Assess the contribution of other agents: Additional agents of low or moderate emetogenic risk generally increase the overall regimen emetogenicity by one level above the most emetogenic agent
  3. Agents of minimal emetogenic risk do not generally change the overall classification
  4. Specific combinations may have their own defined classification — for example, AC (doxorubicin + cyclophosphamide) is classified as HEC regardless of individual agent doses

References

  1. Hesketh PJ. “Chemotherapy-induced nausea and vomiting.” New England Journal of Medicine, 358(23): 2482–2494, 2008. DOI: 10.1056/NEJMra0706547 ↩︎

  2. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. “Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.” Supportive Care in Cancer, 6(3): 244–247, 1998. DOI: 10.1007/s005200050164 ↩︎

  3. Hesketh PJ, Kris MG, Basch E, et al. “Antiemetics: ASCO Guideline Update.” Journal of Clinical Oncology, 38(24): 2782–2797, 2020. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.20.01296 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  4. Roila F, Molassiotis A, Herrstedt J, et al. “2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.” Annals of Oncology, 27(suppl 5): v119–v133, 2016. Multinational Association of Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO). Updated through 2023 consensus. DOI: 10.1093/annonc/mdw270 ↩︎ ↩︎ ↩︎ ↩︎

  5. National Comprehensive Cancer Network (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Antiemesis.” Version 1.2025. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  6. Hesketh PJ, Kris MG, Basch E, et al. “Antiemetics: ASCO Guideline Update.” Journal of Clinical Oncology, 38(24): 2782–2797, 2020 (Supplemental Data Tables — Oral Agents). American Society of Clinical Oncology (ASCO). ↩︎

  7. Molassiotis A, Aapro M, Dicato M, et al. “Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.” Journal of Pain and Symptom Management, 47(5): 839–848, 2014. DOI: 10.1016/j.jpainsymman.2013.06.012 ↩︎